Validation vs Marketing: How to Read a Health-Tech Claim Honestly

A validated claim tells you what was tested, who it was tested on, what it was compared against, and what measurably changed. A marketing claim tells you how the product is supposed to make you feel about it. The fastest way to separate the two is to ask of any sentence in a brochure: could this be false, and would we have found out? If the claim is built so that no result could ever have contradicted it, you are reading marketing, however clinical the font looks.

The line is not a moral one. Marketing is a legitimate craft, and most of the people writing these claims are working in good faith on genuinely hard problems. The trouble is that the two kinds of claim often wear the same clothes. Both can carry a percentage, a logo, a confident verb. So this is a piece about reading, not about catching anyone out. Learn to see the structure underneath the sentence and you stop needing to trust the tone.

What is the difference between a validated claim and a marketing claim?

Here is a definition worth keeping. A validated claim was put in a position where it could have failed and did not. A marketing claim was written to sound true. The grammar can be identical, so the difference lives in whether there was ever a real chance of a different answer.

Take two sentences about the same hypothetical tool. The first: "clinicians love using it." The second: "across nine clinics, documentation time per visit fell against the same clinics' baseline, and the effect held after we accounted for clinic size." Only the second took a risk. The sample could have been too small, the comparison could have shown nothing, the adjustment could have erased the effect. It survived a test. The first sentence cannot be wrong, which is exactly why it tells you nothing.

What does a validated claim actually contain?

A claim earns the word "validated" when it answers four questions on its own, without you having to email anyone.

It names the population. Not "patients," but which patients: their age range, setting, disease stage, the country and system they were treated in. A result is a statement about the people it was measured on, and it does not automatically travel to people who differ. My own work on ethnic differences in the relationship between insulin sensitivity and insulin response is a standing reminder that a relationship which is clean in one group can shift in another. The honest version of a claim tells you whose biology it describes.

It names the comparator. Better than what? "Improves outcomes" with no comparator floats free of any baseline, which makes it sound stronger than "better than what a competent clinician does today." Improvement is a relationship between two states, and a claim with only one of them is incomplete by construction.

It names the outcome, and it names it in advance. A trustworthy result was decided before the data came in: this is what we will measure, and this is what counts as success. Collecting everything and then announcing whichever number looks best is one of the most human and most misleading habits in the field, because the people doing it usually believe their own story.

It names the magnitude and the uncertainty. "Reduced risk" without a number, or a number with no sense of how precise it is, is decoration. A large average benefit with enormous uncertainty and a small benefit measured precisely are very different things wearing the same headline.

What does a brochure look like instead?

A brochure substitutes proxies for these four things, and the proxies are seductive because they are real, just not relevant to the question you are asking.

The most common proxy is the input. "Trained on ten million records," "built with a leading academic center," "developed by clinicians." These describe how much effort went in, not what came out, and effort is not evidence. A model trained on enormous data can still fail on your patients. The size of the kitchen does not tell you how the meal tastes.

A second proxy is the demonstration. A smooth screen recording where the tool does the right thing shows only that it can do the right thing once, on a case the team chose. The real question is what happens across the messy distribution of cases nobody curated.

A third proxy is the endorsement. Awards, pilots, and prestigious partners are genuine signals of seriousness, and I have been glad to receive recognition for work I believe in. But an award is a judgment about promise, and a pilot is an experiment that has not yet reported. A common trap is reading "selected for a program" as "shown to work," when at most it means "judged worth finding out about."

The cleanest tell is the unfalsifiable verb. Words like "empower," "transform," and "seamless" do emotional work, not evidentiary work. You cannot design a study whose failure would force you to retract the word "seamless." A claim that could not have come out any other way is describing intent, not outcome.

How can you check a claim in a few minutes?

You do not need a statistics degree to apply pressure, just a short list of questions and the patience to notice when they are dodged. Ask what would have counted as failure. If the team cannot describe a result that would have disappointed them, the study was not really a test. Ask who it was measured on, ask better than what, and ask to see the prespecified outcome with the size of the effect and its uncertainty, in plain numbers.

Then notice the texture of the answers. Validated work tends to volunteer its own limits, because the people who did it spent months living with those limits, and a claim with no stated weaknesses is usually just younger, or less examined. There is an asymmetry to lean on: it is hard to fake a comparator and a prespecified endpoint, and easy to fake a feeling of confidence. So weight your attention toward the parts of a claim that would have been expensive to fabricate. A specific population, a registered protocol, an external test site, an admitted limitation: these cost something to produce, which is part of why they carry information.

Why this distinction protects everyone, including the builders

I have spent years on the building side, helping develop a clinical decision-support system and put it through a randomized trial across more than forty clinics, so I am sympathetic to how the confusion happens. Evidence is slow, the pressure to describe your product warmly is constant, and the gap between "we believe this helps" and "we have shown this helps" can feel like a technicality when you are sure of your own work. It is not a technicality. It is the difference between a hope and a finding. And holding the line helps the good products too: when buyers read for validation, the teams that did the harder, slower work get rewarded for it instead of being drowned out by whoever wrote the most confident sentence.

This article is educational and reflects my own view as a researcher. It is not medical advice, and if a claim concerns your own care or a tool your clinicians might use, talk it through with them.